Observational studyEuropean radiology experimental2026
Interpretable prediction of macrotrabecular-massive HCC and recurrence-free survival by integrating MRI LI-RADS features with deep learning habitat radiomics.
Observational study in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveMacrotrabecular-massive (MTM+) hepatocellular carcinoma (HCC) is associated with poor prognosis and early recurrence. We developed and validated a nomogram integrating magnetic resonance imaging LI-RADS features with deep learning (DL) habitat radiomics for preoperative prediction of MTM + HCC and stratifying patients according to recurrence-free survival (RFS). MATERIALS AND
methodsIn this retrospective multicenter study, 607 patients with early-stage HCC who underwent curative-intent surgical resection (mean age ± standard deviation, 59.6 ± 10.6 years; 474 males, 133 females) were divided into the training (n = 304), internal validation (n = 131), and external (n = 172) test sets. Liver Imaging Reporting and Data System (LI-RADS) features, LI-RADS categorization, and clinical features were analyzed. Finally, a nomogram integrating LI-RADS features, habitat radiomics, and DL features was developed using multivariate logistic regression. Multivariable Cox regression analyses were performed to identify independent prognostic factors.
resultsAt multivariable analysis, habitat radiomics score, DL score, alpha-fetoprotein (AFP), alanine transferase (ALT), and fat mass were independent predictors of MTM + HCC. The DL habitat radiomics nomogram demonstrated powerful performance with areas under the receiver operating characteristic curve (AUCs) of 0.897 (95% confidence interval [CI]: 0.854-0.940), 0.757 (95% CI: 0.674-0.827), and 0.858 (95% CI: 0.797-0.906) in the training, internal validation, and external test sets, respectively. After multivariable analysis, AFP (p < 0.001) and nomogram-predicted MTM state (p = 0.039) resulted as independent prognostic factors.
conclusionThe nomogram integrating LI-RADS features, habitat radiomics, and DL features accurately identified patients with MTM + HCC and stratified patients by RFS. KEY POINTS: Question Preoperative integrative methods for accurate prediction of MTM + HCC and postoperative recurrence risk stratification remain insufficient. Findings The nomogram integrating LI-RADS features and DL habitat radiomics effectively diagnosed MTM + HCC and showed superior diagnostic performance compared to the Clinical-radiologic model. Relevance statement The nomogram provides a robust, non-invasive tool for preoperative identification of MTM + HCC and recurrence risk stratification, facilitating surgical planning and postoperative surveillance strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.